Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm, Residual × Calcium × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Pancreatic Neoplasms 1 Pain 1 Ovarian Neoplasms 1 Osteoporosis 1 Neoplasms 1 Neoplasm, Residual 1 Myelodysplastic Syndromes 1 Lymphoma 1 Leukemia 1 Kidney Neoplasms 1 Colonic Polyps 1 Carcinoma, Transitional Cell 1 Arthralgia 1 Adenomatous Polyps 1

Interventions

blinatumomab 7 Cyclophosphamide 6 Rituximab 5 Lenalidomide 5 Dexamethasone 5 fludarabine 4 Azacitidine 4 venetoclax 3 fludarabine phosphate 3 Cytarabine 3 thymoglobulin 2 obinutuzumab 2 daratumumab 2 Whole-Body Irradiation 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Methotrexate 2 Melphalan 2 Immunotherapy 2 Imatinib Mesylate 2 Clofarabine 2 Cladribine 2 Calcium Dobesilate 2 Busulfan 2 treosulfan 1 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 talquetamab 1 selinexor 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡